Key Details
Annual ROE
-25.03%Beta
-Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
Aug 04, 2023Recent annual earnings:
Mar 02, 2022Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
24 Feb '23 SMBC Nikko
Neutral23 Feb '23 Raymond James
Market Perform03 Jan '23 Piper Sandler
Overweight11 Nov '22 Raymond James
Outperform31 Aug '22 Raymond James
Strong Buy05 Aug '22 HC Wainwright & Co.
Buy23 May '22 Piper Sandler
Overweight11 May '22 Baird
Neutral06 May '22 Raymond James
Strong Buy16 Mar '22 SMBC Nikko
OutperformScreeners with JNCE included
No data
Market Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
Jounce Therapeutics doesn't have historical dividend data
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Similar stocks
Jounce (JNCE) Up 21% on Accepting Concentra's Buyout Offer
JNCE
Zacks Investment Research28 March 2023
Jounce Therapeutics (JNCE) is set to be acquired by Concentra Biosciences, spurning an all-share merger deal with British biotech firm Redx Pharma.
FAQ
- What is the primary business of Jounce Therapeutics?
- What is the ticker symbol for Jounce Therapeutics?
- Does Jounce Therapeutics pay dividends?
- What sector is Jounce Therapeutics in?
- What industry is Jounce Therapeutics in?
- What country is Jounce Therapeutics based in?
- When did Jounce Therapeutics go public?
- Is Jounce Therapeutics in the S&P 500?
- Is Jounce Therapeutics in the NASDAQ 100?
- Is Jounce Therapeutics in the Dow Jones?
- When was Jounce Therapeutics's last earnings report?
- When does Jounce Therapeutics report earnings?
- Should I buy Jounce Therapeutics stock now?
What is the primary business of Jounce Therapeutics?
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. It develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. The company is also developing JTX-8064, a monoclonal antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; and Pimivalimab, an anti-PD-1 antibody for combination therapy. In addition, its preclinical products are JTX-1484, a monoclonal antibody designed to reduce myeloid-mediated immune suppression; and JTX-2134, a monoclonal antibody designed to reduce myeloid-mediated immune suppression and activate T and NK cells. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.
What is the ticker symbol for Jounce Therapeutics?
The ticker symbol for Jounce Therapeutics is NASDAQ:JNCE
Does Jounce Therapeutics pay dividends?
No, Jounce Therapeutics does not pay dividends
What sector is Jounce Therapeutics in?
Jounce Therapeutics is in the Healthcare sector
What industry is Jounce Therapeutics in?
Jounce Therapeutics is in the Biotechnology industry
What country is Jounce Therapeutics based in?
Jounce Therapeutics is headquartered in United States
When did Jounce Therapeutics go public?
Jounce Therapeutics's initial public offering (IPO) was on 26 January 2017
Is Jounce Therapeutics in the S&P 500?
No, Jounce Therapeutics is not included in the S&P 500 index
Is Jounce Therapeutics in the NASDAQ 100?
No, Jounce Therapeutics is not included in the NASDAQ 100 index
Is Jounce Therapeutics in the Dow Jones?
No, Jounce Therapeutics is not included in the Dow Jones index
When was Jounce Therapeutics's last earnings report?
Jounce Therapeutics's most recent earnings report was on 4 August 2023
When does Jounce Therapeutics report earnings?
The date for Jounce Therapeutics's next earnings report has not been announced yet
Should I buy Jounce Therapeutics stock now?
As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions